I figure that’s why the SP dropped, it’s seen as a surrogate that the CCF trials might be a failure. And yeah GI bleeding in LVAD patients is a tiny market compared to heart failure as a whole.
that said, as a GP I imagine a good result in the P3 chronic back pain trial and commercial release would be a game changer - think how much less targin and tramadol you’ll have to dish out!l. I see this as being the company maker for MSB, the mechanism of action in terms of disk regeneration and reducing inflammation makes more sense to me than randomly injecting stem cells into a failing heart.
Any news from the AGM?, page-88
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |